follow failur epacadostat melanoma cut pt
maintain ow rate back failur initi take see
 thought primari endpoint miss think share
over-correct trade level reflect almost zero pipelin valu
remov valu attribut epacadostat npv stop valuat given
low po tumor type discuss merck cfo rob davi
today sound like merck havent yet made decis viabil
futur combo trial keytruda epacadostat nevertheless remov valu
model big question deserv valu
pipelin look next month well clariti us baricitinib
approv april/jun ruxolitinib gvhd initi fgf phase data
pivot data itacitinib well that even mention valu
earlier-stag oncolog program arginas gitr bromodomain etc
get weak today nbi index vs wrong
po confid assess floor valu
jakafi/baricitinib royalti cash valu assum pt
rest pipelin notabl divers wholli own asset high valu
market oncolog make view strateg attract
revis valuat valu exclud pipelin
contribut epacadostat pt base sotp npv analysi forecast
sale jakafi baricitinib patent expir termin valu use
discount rate deriv valu jakafi baricitinib
royalti broader pipelin net cash
model chang updat model remov guid sg
expens epacadostat prelaunch activ cut
expect wind-down epacadostat trial revenu assumpt remain
unchang forecast non-gaap ep non-
previous includ epacadostat sale
model page detail
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight compel mix
grow commerci asset interest pipelin
asset exclud epacadostat
epacadostat key pipelin driver compani
earlier pipelin program could result
share upsid also expect jakafi peak
royalti baricitinib repres
ww compel commerci perform
success earlier pipelin asset across portfolio
ww compel commerci perform
success earlier pipelin asset across portfolio
given today epacadostat updat manag commentari expens
updat model specif remov guid sg
expens epacadostat prelaunch activ cut
expect wind-down epacadostat trial also adjust expens
reflect new trend revenu assumpt remain unchang forecast
non-gaap ep non-gaap
figur detail
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
